Immix Biopharma Inc. has unveiled its latest presentation focusing on pioneering cell therapy for AL Amyloidosis and other serious diseases, with a dedicated team working on the development of NXC-201. This sterically-optimized CAR-T construct, developed through the N-GENIUS platform, features a "digital filter" that reduces non-specific activation, resulting in improved tolerability. The presentation highlights Immix's significant milestones, including FDA Orphan Drug Designation and Regenerative Medicine Advanced Therapy Designation for NXC-201, and reports on various data from clinical trials. The company plans to submit for FDA approval of NXC-201 in the coming years, with interim and final readouts scheduled. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.